Bibliography
- Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11
- El-serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005;100(6):1243-50
- Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135(4):1383-91; 1391.e1-5
- Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 2005;22(2):79-94
- Hershcovici T, Fass R. Nonerosive Reflux Disease (NERD) - an update. J Neurogastroenterol Motil 2010;16(1):8-21
- Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies. Aliment Pharmacol Ther 2009;29(7):731-41
- Vakil N, Van zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900-20
- Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308-28
- Gremse DA. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. Expert Opin Pharmacother 2001;2(10):1663-70
- Metz DC, Vakily M, Dixit T, et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009;29(9):928-37
- Vakily M, Zhang W, Wu J, et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009;25(3):627-38
- Lee RD, Vakily M, Mulford D, et al. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor--evidence for dosing flexibility. Aliment Pharmacol Ther 2009;29(8):824-33
- Available from: http://www.dexilanthcp.com/dosing [Accessed 21 December 2013]
- Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol 2011;106(3):421-31
- Peura DA, Metz DC, Dabholkar AH, et al. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther 2009;30(10):1010-21
- Metz DC, Howden CW, Perez MC, et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009;29(7):742-54
- Tleyjeh IM, Bin abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One 2012;7(12):e50836
- Johnson DA, Oldfield EC. Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol 2013;11(5):458-64
- Metz DC, Howden CW, Perez MC, et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009;29(7):742-54
- Available from: http://www.hanmipharm.com/eng/release/board_read.asp?seq=549&board_id=7 [Accessed 16 February 2014]
- Available from: http://www.hanmipharm.com/eng/release/board_read.asp?seq=652&board_id=7 [Accessed 16 February 2014]
- Available from: http://www.amneal.com/headlines/archive/ESGPR-002_Eso_Generic_Release_FINAL [Accessed 16 February 2014]
- Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=61a5a84e-0194-4f11-91f8-83d7ac404932 [Accessed 16 February 2014]
- Sips AJ, Van der vijgh WJ, Barto R, et al. Intestinal absorption of strontium chloride in healthy volunteers: pharmacokinetics and reproducibility. Br J Clin Pharmacol 1996;41(6):543-9
- Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J 2012;5(Suppl 1):i3-i14
- Holbein ME, Berglund JP. Understanding Food and Drug Administration regulatory requirements for an investigational device exemption for sponsor-investigators. J Investig Med 2012;60(7):987-94
- Available from: http://www1.astrazeneca-us.com/pi/Nexium [Accessed 16 February 2014]
- Available from: http://www.hanmipharm.com/eng/release/board_read.asp?seq=564&board_id=7 [Accessed 16 February 2014]
- Pors nielsen S. The biological role of strontium. Bone 2004;35(3):583-8
- Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/01/WC500159375 [Accessed 16 February 2014]
- Available from: http://apps.who.int/iris/bitstream/10665/44280/1/9789241530774_eng?ua=1 [Accessed 16 February 2014]
- Hassan-alin M, Andersson T, Niazi M, et al. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 2005;60(11):779-84
- Abelö A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000;28(8):966-72
- Andersson T, Röhss K, Bredberg E, et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001;15(10):1563-9
- Lindberg P, Keeling D, Fryklund J, et al. Review article: esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 2003;17(4):481-8
- Wrighton SA, Vandenbranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 1996;24(5):461-73
- Zanger UM, Turpeinen M, Klein K, et al. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392(6):1093-108
- Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41(12):913-58
- Sahara S, Sugimoto M, Uotani T, et al. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther 2013;38(9):1129-37
- Available from: http://www.toxicology.org/ai/pub/tox/2013ToxSup [Accessed 16 February 2014]
- Moon B, Lee S, Han K, et al. Influence of clinical demographic factors in successful eradication of Helicobacter pylori [abstract]. Helicobacter 2011;16(Suppl 1):119:abstract P07.13
- Van soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006;24(2):377-85
- Available from: http://www.goodrx.com/dexilant [Accessed 16 February 2014]
- Available from: https://www.dexilant.com/Savings.aspx [Accessed 16 February 2014]
- Available from: http://www.goodrx.com/omeprazole [Accessed 16 February 2014]
- Available from: http://www.goodrx.com/esomeprazole-strontium [Accessed 16 February 2014]
- Available from: http://www.goodrx.com/nexium [Accessed 16 February 2014]
- Available from: https://www.purplepill.com/taking-nexium/card.aspx?_ziplist=disable [Accessed 16 February 2014]